Agenda. Frequent Scenario WS I: Treatment Comparisons and Network Meta-Analysis: Learning the Basics
|
|
- Eunice Garrett
- 5 years ago
- Views:
Transcription
1 WS I: onducting & Interpreting Indirect Treatment omparisons and Network Meta-nalysis: Learning the asics onducted by members of the ISPOR Indirect Treatment omparisons Task Force Joe appelleri PhD MPH Jeroen P Jansen PhD Neil Hawkins PhD Rachael Fleurence PhD genda ackground oncepts Example Reporting and interpreting results Q & Indirect Treatment omparisons and Network Meta-nalysis: ackground Joe appelleri Frequent Scenario New drugs are often compared with placebo or standard care, but not against each other, in trials aimed to contribute (as expeditiously as possible) toward obtaining approval for drug licensing ommercial incentive to compare the new treatment with an active control may be wanting Such commercial impetus may be lacking because it is not practical -- drugs are still investigational and there are constraints due to small sample sizes and short durations of follow-up cknowledged Value of Indirect Treatment omparisons vailable treatments tend to increase over time For example, a large number of different (old and new) drugs are available for the treatment of depressive and other mental disorders How to makes sense of it all? linical, patients, and health-policy makers often need to decide which treatment is best Make sense of a complex set of treatments Primary: comparison between active treatments Secondary: pure effect of drug (vs. placebo) Select the best choice(s) of treatment 1
2 Value of Indirect Treatment omparisons Regimes for the Treatment of hildren with cute Pyelonephritis When there is no or insufficient evidence from direct comparison trials, it may be possible, in theory, to use results of different trials to estimate the relative efficacy of different treatments Many interventions have not been directly compared in randomized controlled trials (RTs) Over the period 1971-, 54 trials included over 1 different chemotherapy regimens for advanced non-small-cell lung cancer but direct evidence from at least 1 individuals is available on only two regimens (Lancet 6; 368: ) Despite mounting evidence from 18 trials spanning and evaluating 4 regimens, evidence is available only on a few direct comparisons. Source: Ioannidis. Lancet 6; 368: Value of Indirect Treatment omparisons Offers the opportunity to compare what may not have been otherwise compared Different therapeutic classes Different drugs within the same class Different doses of the same drug General Principles: From Theory to Practice Guidelines are useful to support the appropriate use of certain methods like network meta-analysis pplication of indirect comparisons should be based on the scientific merits of the network meta-analysis -- not on their results per se General Principles Well-conducted RTs provide the most valid estimates of the relative efficacy of competing health-care interventions dvocate their development and use whenever possible, with replication Well-conducted observational studies also have merit General Principles Ensure that the use of network metaanalysis adheres to certain standards and assumptions that can be tested or evaluated Doing so will make this method more credible
3 Indirect Treatment omparisons and Network Meta-nalysis: The oncepts Jeroen P Jansen Networks of evidence efinitions De nalysis & synthesis methods losed loops in network: combination of direct and indirect evidence nchored IT (or adusted IT) Mixed Treatment omparison Network meta-analysis Step wise approach (multiple sequential meta-analyses, followed by indirect comparison of pooled pairwise results) Simultaneous evidence synthesis of all pairwise comparisons across the range of interventions Models without covariates Treatment*covariate interactions in meta-regression models to improve similarity / consistency assumptions and explain heterogeneity Frequentist framework ayesian framework (probabilistic interpretation of uncertainty and ranking of interventions) Indirect comparison Indirect comparison Observed trial data omponents of treatment effect Drug Drug Trial 1 Trial Standardize placebo treatment Drug Drug Intervention arm Trial 1 Intervention arm Trial -subtracted effect d d d d d d Drug Drug Drug Drug Source: Jansen et al., 8 RT 1 Is an indirect comparison biased? Tx 61% 4% 4 weeks RR=.5 RT 1 Is an indirect comparison biased? Tx 61% 4% 4 weeks RR=.5 RT Tx 63% RR=.1 3% 4 weeks RT Tx 63% RR=.1 3% 4 weeks RT 3 nchored Indirect comparison Tx 4% RR=.1 RR=.5 /.1=1. % 3 weeks No bias, because differences in study characteristics across trials do not influence the RR RT 3 Tx 5% RR=.5 % 36 weeks ias in anchored indirect comparison of trial 1 with trail 3, because there are differences in study follow-up across trials that do influence the RR 3
4 Mixed Treatment omparisons d d Similarity and onsistency assumptions With an indirect comparison and MT the comparability of the different types of studies must be considered because the value of randomization does not hold across trials. D d dd Heterogeneity variation in the same relative treatment effect between studies Similarity assumption If there is an imbalance in the distribution of effect modifiers (treatment x covariate interactions) between trials then an indirect comparison or MT is biased. Direct estimate D Indirect estimate Evidence inconsistency discrepancy between different types of comparisons omparisons -, - & - are consistent onsistency relates to the loops of evidence Source: Jansen et al., 8 Source: ooper et al., 9, Jansen et al., 8 Indirect comparison: -step approach Simultaneous evidence synthesis & indirect comparison with regression model 1a) Meta-analysis of trials d d ) Obtain indirect estimate of the efficacy of Tx vs given the pooled results of the meta-analyses d d d D d d d dd k-1 basic parameters: d, d, d D (Priors needed for these in ayesian model) Remaining contrasts are functional parameters, e.g : d =d -d, d D =d D -d, d D =d D -d d D,, total of k(k-1)/ contrasts 1b) Meta-analysis of trials Direct estimate Indirect estimate Source: Mapi Jansen Values et al., 8 Source: Jansen et al., 8 1 study Fixed effects meta-analysis η k d k k Noise / random error Observed effect in individual studies Underlying effect η k d k k 4
5 Fixed effects network metaanalysis model Random effects metaanalysis η k b b d bk d b k d b b,,, k,, D, if k b if k 'after' b d Underlying effects with heterogeneity η ~ N d, k k η d k bk b b ~ N Random effects network meta-analysis bk b,,, k,, D, d, ~ Nd d, bk k b if k b if k 'after' b ayes Theorem Posterior Prior Likelihood ayes Theorem Difference between frequentist and ayesian output μ Tx Tx Frequentist output: Point estimate (with 95%I) No significant difference between Tx and Tx Probability that Tx is better Probability that Tx is better 75% Probability that Tx is better than Tx ayesian output: Probability distribution μ Tx Tx dapted from Hollenbeak,ISPOR 4 5
6 Drug Eluting Stents for oronary rtery Disease Indirect Treatment omparisons and Network Meta-nalysis: Example Neil Hawkins omparators are Metal Stent () Paclitaxel Eluting Stent () Sirolimus Eluting Stent () inary Endpoint Target lesion revasculariation 17,69 subects in 37 studies Study 16 Study 31 Study 3 Study 33 Study 34 Study 35 Study 8 Study 1 Study 14 Study 15 Study 18 Study Study Study 3 Study 4 Study 5 Study 6 Study 7 Study 36 Study 4 Study 5 Study 6 Study 7 Study 1 Study 11 Study 1 Study 13 Study 17 Study 19 Study Study 1 Study 8 Study 9 Study 3 Study 3 Study 37 Study 9 Network of trial evidence Odds Ratio of versus (95% I) Direct comparisons form a network of evidence OR =.5 (.18 to.35) Odds Ratio of versus OR =.7 (.61 to.87) Odds Ratio of versus OR =.43 (.31 to.58) Network meta-analysis Treatment effects (log hazard ratios) are estimated for each treatment ( and ) compared to : β, β Values are estimated to best fit the observed trial data: Log transf. Odds Ratio of vs : Ln OR = β β Ln OR = β Ln OR = β Results of pairwise comparisons Odds Ratio (95% ri) compared to stent: Stent: -.66 (.3 to 3.46 ) 4.1 ( 3 3. to ).38 (.9 to.49 ) ( 1. to 1.96 ) May be estimated using ayesian or Maximum Likelihood techniques.5 (.19 to.31 ).65 (.51 to.8 )
7 L bbe Plots Odds Ratio dusted comparison: ucher et al. method OR and OR are available from pairwise meta-analyses response Response Response response Response Odds Ratio Odds Ratio response Response response Response Response Estimate odds ratios of treatment vs. (OR ) Taking logs: lnor OR OR ucher H, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons 38 in meta-analysis of randomized controlled trials. Journal of linical Epidemiology 1997;5(6):683-9 OR llows the Standard Error (SE) to be alculated on the Log scale: SE lnor ln OR ln OR SElnOR SElnOR vs adusted indirect comparison Treatment omparator Odds Ratio (95% I) Log Odds Ratio (SE).5 (.18 to.35) (.17) onsistency vs : Odds Ratio (95% I) Direct:.7 (.61 to.87) Indirect:.58 (.37 to.9) ombined:.65 (.51 to.8 ).43 (.31 to.58) -.84 (.16).7 (.61 to.87).58 (.37 to.9) -.54 (.3).5 (.18 to.35).43 (.31 to.58) 39 Outline Indirect Treatment omparisons and Network Meta-nalysis: Reporting and interpreting results ssessing the internal and external validity of IT/MT Reporting IT/MT results Interpreting IT/MT results Decision-making in the absence of RTs onclusion Rachael Fleurence 7
8 ssessing the internal and external validity of an IT & network metaanalysis Internal Validity ppropriate identification of studies Quality of included studies onfounding bias violating similarity and consistency assumptions External Validity External validity of included trials 43 Report section Introduction Reporting IT/MT results hecklist Item re the rationale for the study and the study obectives stated clearly? Does the methods section include the following? Description of eligibility criteria Information sources Search strategy Study selection process Data extraction (validity assessment of individual studies) What to look for in the paper clear rationale for the review clear obective or research question that pertains to the network meta-analysis Methods Does the methods section include systematic review of the literature in accordance with entre for Reviews and Dissemination (RD) guidelines and PRISM 44 Reporting IT/MT results Reporting IT/MT results Report section Methods hecklist Item re the outcome measures described? Is there a description of methods for analysis/synthesis of evidence? Do the methods described include the following? Description of analyses methods/models Handling of potential bias/inconsistency nalysis framework re sensitivity analyses presented? What to look for in the paper Justification of outcome measures selected for analysis Description and ustification of statistical model(s) used: Multiple meta-analysis of pairwise comparisons vs. network meta-analysis models; Fixed vs. random effects models; Models without or with covariate (interactions) Description of whether analyses were performed in frequentist vs. ayesian approach. Description of how possible bias / inconsistency was evaluated (either qualitative or quantitative, e.g. comparison of direct evidence with the indirect evidence). If meta-regression models are used rational for selection of covariates in models. Description of comparative effectiveness estimates used for presentation of findings (e.g. odds ratio, relative risk, hazard ratio, difference in change from baseline). Description of whether relative effect measures were transformed into expected (absolute) outcomes (e.g. proportion of responders). Rationale for and description of sensitivity analyses Studies included Prior distributions for model parameters in ayesian framework 45 Report section Results hecklist Item Do the results include a summary of the studies included in the network of evidence? Individual study data? Network of studies? Does the study describe an assessment of model fit? re competing models being compared? What to look for in the paper Description of results of study identification and selection process Table/list of studies with information regarding study design and patient characteristics (that might act as effect modifiers). These are important to udge potential similarity/ consistency issues. Figure of network of studies Table with raw data by study and treatment as used for the analysis/model. (Optionally present relative effects of available direct comparisons of each study) Justification of model results 46 Reporting IT/MT results Reporting IT/MT results Report section Results hecklist Item re the results of the evidence synthesis (IT/MT) presented clearly? Sensitivity/scenario analyses What to look for in the paper Table/ Figure with results for the pairwise comparisons as obtained with analyses; Point estimates and measure of uncertainty (95% intervals) In ayesian framework probability to reflect decision uncertainty (i.e. probability which treatment is best if multiple treatments are being compared, and probability that one treatment is better than the comparator) Description of (different) findings with sensitivity/scenario analysis. Report section hecklist Item What to look for in the paper Discussion Does the discussion include the Summary of findings following? Description/summary of main findings Internal I t l validity of analysis Internal validity (individual trials; publication bias; differences across trials that might violate similarity and consistency it assumptions) External validity Implications of results for target audience Discussion regarding generalisability of findings (given patient population within and across trials in network.) Interpretation of results from a biologic and clinical perspective
9 Interpreting IT/MT results Do the findings apply to the decision problem at hand? Which treatment is most effective in the population of interest? What should we do with multiple endpoints? What about safety, patient preferences and costs? Decision Making in the absence of RTs IT/MT are a good option in the absence of head to head pragmatic randomized trials IT/MT remain a form of observational evidence Should we use comparative observational data? Decisions will benefit from explicit and transparent assessments 49 5 onclusion Indirect Treatment omparisons and Network Meta-nalysis: onclusions Network meta-analysis (IT/MT) are an extension of traditional pairwise meta-analysis IT can provide complementary evidence to direct evidence oth direct and indirect evidence contribute to total body of evidence. The results from indirect evidence in combination with the direct evidence in a MT, may strengthen the assessment between treatments directly evaluated 5 onclusion Similarity and consistency assumption need to hold; Risk of residual confounding bias remains Researchers must continue to conduct RTs with head- to-head comparisons of different treatments Indirect Treatment omparisons and Network Meta-nalysis: Questions & nswers pplications of this method are likely to grow particularly in light of ER 53 9
10 Informal indirect comparison: Odds ratio of haloperidol vs. placebo suggested a greater treatment effect than the odds ratio of risperidone vs. placebo, despite the overlapping confidence intervals WHT N GO WRONG? Risperidone and Haloperidol for Schizophrenia (Outcome: Not linically Improved) Risperidone and Haloperidol for Schizophrenia: What Happened? Similarity assumption violated Patient characteristics, dose of drug, and treatment duration were similar between the two sets of placebo- controlled trials dusted indirect comparison: Favors haloperidol over risperidone Direct comparison: Favors risperidone over haloperidol ombination of direct and indirect: Validity doubtful given their inconsistent evidence Source: Song 9 Source: Song. What is indirect comparison. Part of the What is? series February 9. ut clinical improvement was defined differently -controlled trials of risperidone: % or more greater reduction in total score on the Positive and Negative Syndrome Scale or rief Psychiatric Rating Scale -controlled trials of haloperidol: rated by clinicians using the linical Global Impression or other scales Risperidone and Haloperidol for Schizophrenia: What Happened? onsistency assumption violated for combining direct and indirect estimates Inconsistent results between them may give invalid and misleading results Example: risperidone versus haloperidol for schizophrenia (large I-square = 85%) When results are inconsistent, it is important to investigate possible causes of discrepancy hance, invalid indirect comparison, invalid headto-head comparison, clinically meaningfully heterogeneity across trials 1
VALUE IN HEALTH 14 (2011) available at journal homepage:
VLUE IN HELTH 14 (2011) 417 428 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/jval SIENTIFI REPORT Interpreting Indirect Treatment omparisons and Network Meta-nalysis for
More informationWhat is indirect comparison?
...? series New title Statistics Supported by sanofi-aventis What is indirect comparison? Fujian Song BMed MMed PhD Reader in Research Synthesis, Faculty of Health, University of East Anglia Indirect comparison
More information5/10/2010. ISPOR Good Research Practices for Comparative Effectiveness Research: Indirect Treatment Comparisons Task Force
ISPOR Good Research Practices for Comparative Effectiveness Research: Indirect Treatment Comparisons Task Force Presentation of Two Draft Reports 17 May 2010 ITC Task Force: Leadership Team Lieven Annemans
More informationNetwork Meta-Analysis for Comparative Effectiveness Research
Network Meta-Analysis for Comparative Effectiveness Research Joseph C. Cappelleri, Ph.D., M.P.H. Pfizer Inc Groton, CT e-mail:joseph.c.cappelleri@pfizer.com Oral presentation at the 19 th Annual Biopharmaceutical
More informationISPOR Task Force Report: ITC & NMA Study Questionnaire
INDIRECT TREATMENT COMPARISON / NETWORK META-ANALYSIS STUDY QUESTIONNAIRE TO ASSESS RELEVANCE AND CREDIBILITY TO INFORM HEALTHCARE DECISION-MAKING: AN ISPOR-AMCP-NPC GOOD PRACTICE TASK FORCE REPORT DRAFT
More informationComparative Effectiveness Research Collaborative Initiative (CER-CI) PART 1: INTERPRETING OUTCOMES RESEARCH STUDIES FOR HEALTH CARE DECISION MAKERS
Comparative Effectiveness Research Collaborative Initiative (CER-CI) PART 1: INTERPRETING OUTCOMES RESEARCH STUDIES FOR HEALTH CARE DECISION MAKERS ASSESSING NETWORK META ANALYSIS STUDIES: A PROPOSED MEASUREMENT
More informationComparative Effectiveness Research Collaborative Initiative (CER-CI) PART 1: INTERPRETING OUTCOMES RESEARCH STUDIES FOR HEALTH CARE DECISION MAKERS
Comparative Effectiveness Research Collaborative Initiative (CER-CI) PART 1: INTERPRETING OUTCOMES RESEARCH STUDIES FOR HEALTH CARE DECISION MAKERS HEALTH EVIDENCE FOR DECISION MAKING: ASSESSMENT TOOL
More informationIndirect Comparisons: heroism or heresy. Neil Hawkins With acknowledgements to Sarah DeWilde
Indirect Comparisons: heroism or heresy Neil Hawkins With acknowledgements to Sarah DeWilde 1 Outline Brief introduction to indirect comparisons Two practical examples Heroism or Heresy? 2 A Taxonomy of
More informationGUIDELINE COMPARATORS & COMPARISONS:
GUIDELINE COMPARATORS & COMPARISONS: Direct and indirect comparisons Adapted version (2015) based on COMPARATORS & COMPARISONS: Direct and indirect comparisons - February 2013 The primary objective of
More informationNetwork meta-analysis using data from distributed health data networks
Network meta-analysis using data from distributed health data networks general framework based on an application using acute myocardial infarction in association with use of anti-diabetic agents Chris
More informationSystematic reviews and meta-analyses of observational studies (MOOSE): Checklist.
Systematic reviews and meta-analyses of observational studies (MOOSE): Checklist. MOOSE Checklist Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease:
More informationIndirect and mixed treatment comparisons in arthritis research
RHEUMTOLOGY Rheumatology 2011;50:iv5 iv9 doi:10.1093/rheumatology/ker241 Indirect and mixed treatment comparisons in arthritis research nthony E. des 1, Jason Madan 1 and Nicky J. Welton 1 bstract Evidence
More informationStatistical considerations in indirect comparisons and network meta-analysis
Statistical considerations in indirect comparisons and network meta-analysis Said Business School, Oxford, UK March 18-19, 2013 Cochrane Comparing Multiple Interventions Methods Group Oxford Training event,
More informationStatistical considerations in indirect comparisons and network meta-analysis
Statistical considerations in indirect comparisons and network meta-analysis Said Business School, Oxford, UK March 18-19, 2013 Cochrane Comparing Multiple Interventions Methods Group Oxford Training event,
More informationStatistical considerations in indirect comparisons and network meta-analysis
Statistical considerations in indirect comparisons and network meta-analysis Said Business School, Oxford, UK March 18-19, 2013 Cochrane Comparing Multiple Interventions Methods Group Oxford Training event,
More informationMeta-Analysis. Zifei Liu. Biological and Agricultural Engineering
Meta-Analysis Zifei Liu What is a meta-analysis; why perform a metaanalysis? How a meta-analysis work some basic concepts and principles Steps of Meta-analysis Cautions on meta-analysis 2 What is Meta-analysis
More informationNetzwerk-Meta-Analysen und indirekte Vergleiche: Erhoḧte (Un)Sicherheit?
Netzwerk-Meta-Analysen und indirekte Vergleiche: Erhoḧte (Un)Sicherheit? Prof. Peter Jüni MD FESC Institute of Social and Preventive Medicine and CTU Bern, University of Bern Is there increased certainty?
More informationComparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods
Comparing treatments evaluated in studies forming disconnected networks of evidence: A review of methods John W Stevens Reader in Decision Science University of Sheffield EFPSI European Statistical Meeting
More informationThe role of MTM in Overviews of Reviews
Deborah Caldwell The role of MTM in Overviews of Reviews d.m.caldwell@bristol.ac.uk Comparing Multiple Interventions Methods Group Keystone, 2010 Why we need overviews of reviews Explosion in RCTs necessitated
More informationAddressing multiple treatments II: multiple-treatments meta-analysis basic methods
Deborah Caldwell and Georgia Salanti d.m.caldwell@bristol.ac.uk Addressing multiple treatments II: multiple-treatments meta-analysis basic methods Keystone, 2010 18 th Cochrane Colloquium, 18 th to 22
More informationDevelopment of restricted mean survival time difference in network metaanalysis based on data from MACNPC update.
Development of restricted mean survival time difference in network metaanalysis based on data from MACNPC update. Claire Petit, Pierre Blanchard, Jean-Pierre Pignon, Béranger Lueza June 2017 CONTENTS Context...
More informationEvaluating the Quality of Evidence from a Network Meta- Analysis
Evaluating the Quality of Evidence from a Network Meta- Analysis Georgia Salanti 1, Cinzia Del Giovane 2, Anna Chaimani 1, Deborah M. Caldwell 3, Julian P. T. Higgins 3,4 * 1 Department of Hygiene and
More informationMethods for assessing consistency in Mixed Treatment Comparison Meta-analysis
Methods for assessing consistency in Mixed Treatment Comparison Meta-analysis Sofia Dias, NJ Welton, AE Ades RSS 2009, Edinburgh Department of Community Based Medicine Overview Mixed Treatment Comparison
More informationStatistical modelling issues arising from PK/PD bridging in paediatrics
Statistical modelling issues arising from PK/P bridging in paediatrics The Trileptal Example Jerry R. Nedelman, Modeling and Simulation, Novartis Workshop on Modelling in Paediatric rug evelopment and
More informationWhat are my chances?
What are my chances? John Wong, MD Chief, Division of Clinical Decision Making Tufts Medical Center Tufts University School of Medicine Sex-specific Reporting of Scientific Research: Workshop Institute
More informationCTU Bern, Bern University Hospital & Institute of Social and Preventive Medicine (ISPM)
10 TH ANNIVERSARY OF THE CHMG Network Meta-Analyses Sven Trelle CTU Bern, Bern University Hospital & Institute of Social and Preventive Medicine (ISPM) Outline > Standard meta-analyses > Principles of
More informationMeta-analysis to compare combination therapies: A case study in kidney transplantation
Meta-analysis to compare combination therapies: A case study in kidney transplantation Steffen Witte, Amy Racine, Heinz Schmidli Novartis Pharma AG, Switzerland, Basel, June 2009 Outline Introduction Methods
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2014
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2014 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationGRADE. Grading of Recommendations Assessment, Development and Evaluation. British Association of Dermatologists April 2018
GRADE Grading of Recommendations Assessment, Development and Evaluation British Association of Dermatologists April 2018 Previous grading system Level of evidence Strength of recommendation Level of evidence
More informationSystematic Reviews and Meta- Analysis in Kidney Transplantation
Systematic Reviews and Meta- Analysis in Kidney Transplantation Greg Knoll MD MSc Associate Professor of Medicine Medical Director, Kidney Transplantation University of Ottawa and The Ottawa Hospital KRESCENT
More informationCritical appraisal: Systematic Review & Meta-analysis
Critical appraisal: Systematic Review & Meta-analysis Atiporn Ingsathit MD.PhD. Section for Clinical Epidemiology and biostatistics Faculty of Medicine Ramathibodi Hospital Mahidol University What is a
More informationResults. NeuRA Hypnosis June 2016
Introduction may be experienced as an altered state of consciousness or as a state of relaxation. There is no agreed framework for administering hypnosis, but the procedure often involves induction (such
More informationStandards for the reporting of new Cochrane Intervention Reviews
Methodological Expectations of Cochrane Intervention Reviews (MECIR) Standards for the reporting of new Cochrane Intervention Reviews 24 September 2012 Preface The standards below summarize proposed attributes
More informationLive WebEx meeting agenda
10:00am 10:30am Using OpenMeta[Analyst] to extract quantitative data from published literature Live WebEx meeting agenda August 25, 10:00am-12:00pm ET 10:30am 11:20am Lecture (this will be recorded) 11:20am
More informationPrinciples of meta-analysis
Principles of meta-analysis 1 The popularity of meta-analyses Search on 22 October 2015 10000 9000 8156 8875 8000 7000 6554 6000 5000 4852 4000 3000 2000 1000 0 1 1 1 272 334 371 323 386 429 482 596 639
More information'Summary of findings' tables in network meta-analysis (NMA)
'Summary of findings' tables in network meta-analysis (NMA) Juan José Yepes-Nuñez MD, MSc, PhD candidate Department of Health Research Methods, Evidence, and Impact (HEI), McMaster University, Canada Professor,
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationFundamental Clinical Trial Design
Design, Monitoring, and Analysis of Clinical Trials Session 1 Overview and Introduction Overview Scott S. Emerson, M.D., Ph.D. Professor of Biostatistics, University of Washington February 17-19, 2003
More informationNetwork Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications
Network Meta-Analyses of Antipsychotics for Schizophrenia: Clinical Implications JOHN M. DAVIS, MD Professor of Psychiatry University of Illinois at Chicago Chicago, Illinois and STEFAN LEUCHT, MD Klinik
More informationRecent developments for combining evidence within evidence streams: bias-adjusted meta-analysis
EFSA/EBTC Colloquium, 25 October 2017 Recent developments for combining evidence within evidence streams: bias-adjusted meta-analysis Julian Higgins University of Bristol 1 Introduction to concepts Standard
More informationAppendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms
Appendix 1: Supplementary tables [posted as supplied by author] Table A. Details of MeSH Search Terms Stent Bare Metal Stent Drug Eluting Stent MeSH terms Randomized controlled trial, clinical trial, Human,
More informationAssessing cost-effectiveness of drug interventions for schizophrenia Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T
Assessing cost-effectiveness of drug interventions for schizophrenia Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T Record Status This is a critical abstract of an economic evaluation that meets the
More informationCochrane Pregnancy and Childbirth Group Methodological Guidelines
Cochrane Pregnancy and Childbirth Group Methodological Guidelines [Prepared by Simon Gates: July 2009, updated July 2012] These guidelines are intended to aid quality and consistency across the reviews
More informationADDING VALUE AND EXPERTISE FOR SUCCESSFUL MARKET ACCESS. Per Sørensen, Lundbeck A/S
ADDING VALUE AND EXPERTISE FOR SUCCESSFUL MARKET ACCESS Per Sørensen, Lundbeck A/S Market Access - price & reimbursement Situation today within psychiatric and neurological diseases Increased requirements
More informationModels for potentially biased evidence in meta-analysis using empirically based priors
Models for potentially biased evidence in meta-analysis using empirically based priors Nicky Welton Thanks to: Tony Ades, John Carlin, Doug Altman, Jonathan Sterne, Ross Harris RSS Avon Local Group Meeting,
More informationAnimal-assisted therapy
Introduction Animal-assisted interventions use trained animals to help improve physical, mental and social functions in people with schizophrenia. It is a goal-directed intervention in which an animal
More informationApplication of human epidemiological studies to pesticide risk assessment
Workshop What does the future hold for harmonised human health risk assessment of plant protection products? Application of human epidemiological studies to pesticide risk assessment Antonio F. Hernández,
More informationClinical Epidemiology for the uninitiated
Clinical epidemiologist have one foot in clinical care and the other in clinical practice research. As clinical epidemiologists we apply a wide array of scientific principles, strategies and tactics to
More informationTypes of Data. Systematic Reviews: Data Synthesis Professor Jodie Dodd 4/12/2014. Acknowledgements: Emily Bain Australasian Cochrane Centre
Early Nutrition Workshop, December 2014 Systematic Reviews: Data Synthesis Professor Jodie Dodd 1 Types of Data Acknowledgements: Emily Bain Australasian Cochrane Centre 2 1 What are dichotomous outcomes?
More informationDesign and Analysis Plan Quantitative Synthesis of Federally-Funded Teen Pregnancy Prevention Programs HHS Contract #HHSP I 5/2/2016
Design and Analysis Plan Quantitative Synthesis of Federally-Funded Teen Pregnancy Prevention Programs HHS Contract #HHSP233201500069I 5/2/2016 Overview The goal of the meta-analysis is to assess the effects
More informationSurvival Analysis in Clinical Trials: The Need to Implement Improved Methodology
Survival Analysis in Clinical Trials: The Need to Implement Improved Methodology Lucinda (Cindy) Billingham Professor of Biostatistics Director, MRC Midland Hub for Trials Methodology Research Lead Biostatistician,
More information4. Aflibercept showed significant improvement in overall survival (OS), the primary
Cost effectiveness of aflibercept (Zaltrap ) in combination with FOLFIRI in the treatment of adult patients with metastatic colorectal cancer (mcrc) that is resistant to or has progressed after an oxaliplatin
More informationSeeing the Forest & Trees: novel analyses of complex interventions to guide health system decision making
Seeing the Forest & Trees: novel analyses of complex interventions to guide health system decision making Noah Ivers MD CCFP PhD Family Physician, Women s College Hospital Scientist, Women s College Research
More informationUsing Indirect Comparisons to Support a Health Technology Assessment (HTA)
Using Indirect Comparisons to Support a Health Technology Assessment (HTA) Chrissie Fletcher Executive Director & Regional Head Global Biostatistical Science, Amgen Disclaimer The views expressed herein
More informationDistraction techniques
Introduction are a form of coping skills enhancement, taught during cognitive behavioural therapy. These techniques are used to distract and draw attention away from the auditory symptoms of schizophrenia,
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationDiscussion Meeting for MCP-Mod Qualification Opinion Request. Novartis 10 July 2013 EMA, London, UK
Discussion Meeting for MCP-Mod Qualification Opinion Request Novartis 10 July 2013 EMA, London, UK Attendees Face to face: Dr. Frank Bretz Global Statistical Methodology Head, Novartis Dr. Björn Bornkamp
More informationWorkshop 21: INDIRECT TREATMENT COMPARISONS: AN INTERACTIVE WORKSHOP ON CHOOSING THE RIGHT TOOL FOR THE AVAILABLE DATA
Workshop 21: INDIRECT TREATMENT COMPARISONS: AN INTERACTIVE WORKSHOP ON CHOOSING THE RIGHT TOOL FOR THE AVAILABLE DATA ISPOR Europe 2018 Barcelona, Spain Wednesday, 14 November 2018 15:00 16:00 ISPOR Statistical
More informationProblem solving therapy
Introduction People with severe mental illnesses such as schizophrenia may show impairments in problem-solving ability. Remediation interventions such as problem solving skills training can help people
More informationDo the sample size assumptions for a trial. addressing the following question: Among couples with unexplained infertility does
Exercise 4 Do the sample size assumptions for a trial addressing the following question: Among couples with unexplained infertility does a program of up to three IVF cycles compared with up to three FSH
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More informationResults. NeuRA Worldwide incidence April 2016
Introduction The incidence of schizophrenia refers to how many new cases there are per population in a specified time period. It is different from prevalence, which refers to how many existing cases there
More informationResults. NeuRA Treatments for dual diagnosis August 2016
Introduction Many treatments have been targeted to improving symptom severity for people suffering schizophrenia in combination with substance use problems. Studies of dual diagnosis often investigate
More informationObjectives. Information proliferation. Guidelines: Evidence or Expert opinion or???? 21/01/2017. Evidence-based clinical decisions
Guidelines: Evidence or Expert opinion or???? Objectives Need for guidelines? Prakesh Shah Professor, Department of Pediatrics, Mount Sinai Hospital Institute of Health Policy Management and Evaluation
More informationEvidence synthesis with limited studies
Evidence synthesis with limited studies Incorporating genuine prior information about between-study heterogeneity PSI conference 2018 Dr. Shijie (Kate) Ren, Research Fellow, School of Health and Related
More informationApplications of Bayesian methods in health technology assessment
Working Group "Bayes Methods" Göttingen, 06.12.2018 Applications of Bayesian methods in health technology assessment Ralf Bender Institute for Quality and Efficiency in Health Care (IQWiG), Germany Outline
More informationCritical Appraisal Skills. Professor Dyfrig Hughes Health Economist AWMSG
Critical Appraisal Skills Professor Dyfrig Hughes Health Economist AWMSG Critical appraisal of economic evaluations Quality of the underlying evidence Quality of the analysis Quality of reporting 1. Quality
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER ON MISSING DATA
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 15 November 2001 CPMP/EWP/1776/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO
More informationProject Funded under FP7 - HEALTH Grant Agreement no Funded under FP7 - HEALTH Grant Agreement no
Developing methods of HTA for medical devices: WP3 - Methods for comparative effectiveness research of medical devices Final Conference November, 13 th 2015 U. Siebert, P. Schnell-Inderst, C. Iglesias,
More informationComparison of Meta-Analytic Results of Indirect, Direct, and Combined Comparisons of Drugs for Chronic Insomnia in Adults: A Case Study
ORIGINAL ARTICLE Comparison of Meta-Analytic Results of Indirect, Direct, and Combined Comparisons of Drugs for Chronic Insomnia in Adults: A Case Study Ben W. Vandermeer, BSc, MSc, Nina Buscemi, PhD,
More informationTraumatic brain injury
Introduction It is well established that traumatic brain injury increases the risk for a wide range of neuropsychiatric disturbances, however there is little consensus on whether it is a risk factor for
More informationStatistical considerations in indirect comparisons and network meta-analysis
Statistical considerations in indirect comparisons and network meta-analysis Said Business School, Oxford, UK March 18-19, 2013 Cochrane Comparing Multiple Interventions Methods Group Oxford Training event,
More informationDealing with uncertainty in the economic evaluation of health care technologies
Dealing with uncertainty in the economic evaluation of health care technologies Susan Claire Griffin, MSc. This thesis was submitted for the qualification of PhD by publications at the University of York
More informationCopyright GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD
GRADE ING THE QUALITY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS NANCY SANTESSO, RD, PHD ASSISTANT PROFESSOR DEPARTMENT OF CLINICAL EPIDEMIOLOGY AND BIOSTATISTICS, MCMASTER UNIVERSITY Nancy Santesso,
More informationGRADE, Summary of Findings and ConQual Workshop
GRADE, Summary of Findings and ConQual Workshop To discuss Introduction New JBI Levels of Evidence and Grades of Recommendation Moving towards GRADE Summary of Findings tables Qualitative Levels Conclusion
More informationSection A: Clarification on effectiveness data. Licensed population
Section A: Clarification on effectiveness data Licensed population A1: priority question Please provide the information depicted in the following table for each of the subgroups listed below (i.e., 7 tables
More informationNeuRA Sleep disturbance April 2016
Introduction People with schizophrenia may show disturbances in the amount, or the quality of sleep they generally receive. Typically sleep follows a characteristic pattern of four stages, where stage
More informationEvidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co.
Evidence-Based Medicine and Publication Bias Desmond Thompson Merck & Co. Meta-Analysis Defined A meta-analysis is: the statistical combination of two or more separate studies In other words: overview,
More informationThe QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews
The QUOROM Statement: revised recommendations for improving the quality of reports of systematic reviews David Moher 1, Alessandro Liberati 2, Douglas G Altman 3, Jennifer Tetzlaff 1 for the QUOROM Group
More informationLecture Outline. Biost 590: Statistical Consulting. Stages of Scientific Studies. Scientific Method
Biost 590: Statistical Consulting Statistical Classification of Scientific Studies; Approach to Consulting Lecture Outline Statistical Classification of Scientific Studies Statistical Tasks Approach to
More informationIndex. Springer International Publishing Switzerland 2017 T.J. Cleophas, A.H. Zwinderman, Modern Meta-Analysis, DOI /
Index A Adjusted Heterogeneity without Overdispersion, 63 Agenda-driven bias, 40 Agenda-Driven Meta-Analyses, 306 307 Alternative Methods for diagnostic meta-analyses, 133 Antihypertensive effect of potassium,
More informationBayesian approaches to analysing studies and summarizing evidences
Bruxelles, February 10, 2012 Bayesian approaches to analysing studies and summarizing evidences Paolo Bruzzi Clinical Epidemiology Unit National Cancer Research Institute Genova - Italy Conventional Statistical
More informationEconomic evaluation of factorial randomised controlled trials: challenges, methods and recommendations
Research Article Received: 31 May 2016, Accepted: 4 April 2017 Published online 3 May 2017 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/sim.7322 Economic evaluation of factorial randomised
More informationFixed Effect Combining
Meta-Analysis Workshop (part 2) Michael LaValley December 12 th 2014 Villanova University Fixed Effect Combining Each study i provides an effect size estimate d i of the population value For the inverse
More informationBayesian Joint Modelling of Benefit and Risk in Drug Development
Bayesian Joint Modelling of Benefit and Risk in Drug Development EFSPI/PSDM Safety Statistics Meeting Leiden 2017 Disclosure is an employee and shareholder of GSK Data presented is based on human research
More informationAlcohol interventions in secondary and further education
National Institute for Health and Care Excellence Guideline version (Draft for Consultation) Alcohol interventions in secondary and further education NICE guideline: methods NICE guideline Methods
More informationINTRODUCTION TO BAYESIAN REASONING
International Journal of Technology Assessment in Health Care, 17:1 (2001), 9 16. Copyright c 2001 Cambridge University Press. Printed in the U.S.A. INTRODUCTION TO BAYESIAN REASONING John Hornberger Roche
More informationSystematic review with multiple treatment comparison metaanalysis. on interventions for hepatic encephalopathy
Systematic review with multiple treatment comparison metaanalysis on interventions for hepatic encephalopathy Hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome associated with severe
More informationIntroduction to meta-analysis
Introduction to meta-analysis Steps of a Cochrane review 1. define the question 2. plan eligibility criteria 3. plan methods 4. search for studies 5. apply eligibility criteria 6. collect data 7. assess
More informationGLOSSARY OF GENERAL TERMS
GLOSSARY OF GENERAL TERMS Absolute risk reduction Absolute risk reduction (ARR) is the difference between the event rate in the control group (CER) and the event rate in the treated group (EER). ARR =
More informationEditorial considerations for reviews that compare multiple interventions
Editorial considerations for reviews that compare multiple interventions Said Business School, Oxford, UK March 22, 2013 Cochrane Comparing Multiple Interventions Methods Group Oxford Training event, March
More informationIdentifying Peer Influence Effects in Observational Social Network Data: An Evaluation of Propensity Score Methods
Identifying Peer Influence Effects in Observational Social Network Data: An Evaluation of Propensity Score Methods Dean Eckles Department of Communication Stanford University dean@deaneckles.com Abstract
More informationThe RoB 2.0 tool (individually randomized, cross-over trials)
The RoB 2.0 tool (individually randomized, cross-over trials) Study design Randomized parallel group trial Cluster-randomized trial Randomized cross-over or other matched design Specify which outcome is
More informationLearning objectives. Examining the reliability of published research findings
Examining the reliability of published research findings Roger Chou, MD Associate Professor of Medicine Department of Medicine and Department of Medical Informatics and Clinical Epidemiology Scientific
More informationPartitioned survival analysis for decision modelling in health care: a critical review
Partitioned survival analysis for decision modelling in health care: a critical review Marta Soares ISPOR, Glasgow 2017 Acknowledgements: Beth Woods, Eleftherios Sideris, Stephen Palmer (University of
More informationMethod. NeuRA Paliperidone August 2016
Introduction Second generation antipsychotics (sometimes referred to as atypical antipsychotics) are a newer class of antipsychotic medication than first generation typical antipsychotics. Second generation
More informationUsing Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs
Using Statistical Principles to Implement FDA Guidance on Cardiovascular Risk Assessment for Diabetes Drugs David Manner, Brenda Crowe and Linda Shurzinske BASS XVI November 9-13, 2009 Acknowledgements
More informationSetting The setting was secondary care. The economic study was carried out in Belgium.
Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium Neymark N, Gorlia T, Adriaenssen I, Baron B, Piccart M Record
More informationPopulation-adjusted treatment comparisons Overview and recommendations from the NICE Decision Support Unit
Population-adjusted treatment comparisons Overview and recommendations from the NICE Decision Support Unit David M Phillippo, University of Bristol 3 Available from www.nicedsu.org.uk Outline Background
More information